LEXINGTON, Mass., May 29, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:
AGEN), an immuno-oncology company with an extensive pipeline of
agents designed to activate immune response to cancers and
infections, announced the American Society of Clinical Oncology
(ASCO2020) Virtual Scientific Program on AGEN1181 by Dr.
Steven J. O'Day, the Executive
Director of the John Wayne Cancer Institute and Cancer Clinic and
Director of Providence Los Angeles Regional Research.
AGEN1181 is a multifunctional Fc-engineered next generation
anti-CTLA-4 antibody specifically designed to improve the safety
and efficacy of first-generation CTLA-4 antibodies. AGEN1181 is
advancing in the clinic both as monotherapy and in combination with
balstilimab (Agenus's anti-PD-1). Patients receiving this
multifunctional antibody have progressed on prior treatments
including other I-O agents, such as anti-PD-1.
"I am very pleased to report data on AGEN1181 alone and in
combination with balstilimab (anti-PD-1). Preliminary efficacy is
encouraging with objective responses (both complete and partial) as
well as prolonged stable disease in a variety of advanced cancers
progressing after standard therapies," said Dr. Steven O'Day, Executive Director of the John
Wayne Cancer Institute and Cancer Clinic. "Importantly,
unlike first-generation CTLA-4 antibodies, we have seen no evidence
of complement mediated toxicities, such as hypophysitis, with
AGEN1181. These early data, including responses in patients with
CD16 polymorphisms, support the accelerated development of AGEN1181
into multiple tumors, including PD-1 refractory melanoma, NSCLC,
and others."
Abstract:
|
TPS3157
|
Title:
|
AGEN1181, A Clinical
Stage Fc-engineered anti-CTLA-4 Antibody with Improved Therapeutic
Potential for the Treatment of Patients with Advanced
Malignancies
|
Presenter:
|
Dr. Steven J.
O'Day
|
Session:
|
Developmental
Therapeutics—Immunotherapy
|
Date/Time:
|
May 29, 2020;
8:00-11:00AM
|
Conference call scheduled on June 2,
2020
B.Riley FBR Senior Analyst Mayank
Mamtani, will host a conference call for investors on
Tuesday, June 2, 2020 with Dr.
Steven O'Day and Dr. Charles Drake, Co-Director of the Cancer
Immunotherapy Program and Co-Leader of the Tumor Biology &
Microenvironment Program at Columbia
University, and Jennifer
Buell, PhD and President and COO of Agenus, to discuss the
data coming out of the ASCO2020 Virtual Scientific Program.
Date: Tuesday, June 2, 2020
Time: 5:30 PM ET
Dial-in details: Investor access: 800.267.2845/973.413.6102
(Passcode: 842069)
The presentation will be available for on-demand viewing
online at https://meetings.asco.org/am/virtual-program.
About Agenus
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer and
infections. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its AgenTus
Therapeutics subsidiary), and proprietary cancer vaccine platforms.
The Company is equipped with a suite of antibody discovery
platforms and a state-of-the-art GMP manufacturing facility with
the capacity to support clinical programs. Agenus is headquartered
in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and twitter.
Forward-Looking Statements
This press release contains
forward-looking statements that are made pursuant to the safe
harbor provisions of the federal securities laws, including
statements regarding an upcoming presentation at ASCO on Agenus'
clinical data of AGEN1181 alone and in combination with balstilimab
(anti-PD-1), the anticipated benefits of AGEN1181 and clinical
development plans and timelines for AGEN1181. These forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially. These risks and uncertainties
include, among others, the factors described under the Risk Factors
section of our most recent Quarterly Report on Form 10-Q or Annual
Report on Form 10-K filed with the Securities and Exchange
Commission. Agenus cautions investors not to place considerable
reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this press
release, and Agenus undertakes no obligation to update or revise
the statements, other than to the extent required by law. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement.
Contact:
Agenus Inc.
Jennifer
Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
1Clinical benefit includes complete response, partial
response, disease stabilization
View original content to download
multimedia:http://www.prnewswire.com/news-releases/asco-presentation-of-agenus-agen1181-by-dr-steven-oday-301067575.html
SOURCE Agenus